Introduction {#s0001}
============

Tendinopathies are common disorders representing ∼30% of all complaints for pain and functional limitation of the musculoskeletal system in the general population[@CIT0001]. They affect both sedentary individuals, as well as professional and recreational athletes. Inflammation and chronic degeneration are the key conditions in the pathogenesis, and their natural history is influenced by the quality of the tendon tissue, along with mechanical overuse or misuse. Rotator cuff tendons, forearm extensor tendons, and the Achilles tendon are the most commonly afflicted sites[@CIT0001].

Rotator cuff tendinopathy (RCT) is the most common source of shoulder pain, and its prevalence is estimated to be 2--3.8% in the general population[@CIT0002].

Lateral epicondylitis is a common chronic inflammatory degeneration of the wrist extensor tendons at their insertion to the lateral epicondyle of the humerus. It affects 1--3% of the general population, especially between the ages of 30 and 70, without gender predisposition[@CIT0003].

Achilles tendinopathy is the most prevalent tendon disorder among athletes, especially runners, track and field, volleyball, tennis, and soccer players[@CIT0004]. Acute and chronic Achilles tendinopathies are estimated to be almost 50% of all sports-related injuries, and they are generally activity-associated, leading to pain and functional limitation, with diminished athletic performance. Asymptomatic degeneration of the Achilles tendon may also occur in 4% of active adults. The male gender is mostly involved[@CIT0005].

Conservative treatment of tendinopathies includes rest, cryotherapy, non-steroidal anti-inflammatory drugs (NSAIDs), orthotic devices, braces/slings, physiotherapy, and corticosteroid injections. Recently physical therapies have obtained a large consensus in the literature for their effectiveness in the treatment of tendinopathies. The most employed conservative treatments are ultrasound (US), laser therapy, TECAR (Transfer of Energy Capacitive and Resistive) therapy, and extracorporeal shock wave therapy (ESWT). Ten per cent of patients do not respond to conservative management and, for this group of patients, surgery represents the best option[@CIT0006].

Extracorporeal Shock Wave Therapy has shown positive and consistent results in the treatment of musculoskeletal diseases[@CIT0007] ^,^ [@CIT0008].

It has been demonstrated that ESWT is effective for tendinopathy, leading to a success rate ranging from 55--90%. In particular, recovery is achieved in 83% of calcific tendonitis of the shoulder, 55% of sub-acromial impingements, 76% of epicondylitis, 74% of plantar fasciitis, 90% of pertrochanteric bursitis, 82% of Achilles tendinopathy, and 86% of patellar tendinopathy[@CIT0008].

ESWT stimulates soft-tissue healing through inhibition of afferent pain-receptor function, downregulation of expression of inflammatory cytokines, improvement of cellular proliferation, synthesis of extracellular matrix, and enhanced angiogenesis.

Recently several clinical studies have demonstrated that exogenous supplementation with micronutrients can facilitate recovery of tendinopathies[@CIT0009]. The main substances essential for tendon healing include arginine, polyphenols (Vinitrox™ Bio Serae Laboratories SAS, Bram, France), collagen, methyl-sulfonyl-methane (MSM), vitamin C, and bromelain[@CIT0006].

Few studies have verified the effectiveness of co-treatment of tendinopathy based on a combination of ESWT and nutraceutical supplementation.

The goal of this study was to assess the effects of our synergistic therapy using clinical and functional recovery indexes to assess three groups of patients affected by shoulder tendinopathy, lateral elbow tendinopathy, and insertional Achilles tendinopathy.

Materials and methods {#s0002}
=====================

In the period between January 2017 and September 2018 in our orthopedic outpatient clinic, we recruited 90 patients, divided into groups of 30 patients, for each of the following conditions: Achilles tendinopathy, rotator cuff tendinopathy of the shoulder, and lateral epicondylitis of the elbow. The diagnoses were confirmed through clinical evaluation (pain and functional limitation of the affected joint) as well as radiographic evidence. In particular, Achilles tendinitis and lateral epicondylitis were confirmed by ultrasonography, and shoulder tendinopathy was confirmed by MRI.

For each condition, the patients were further sub-divided into a control group, treated with ESWT, and an experimental group, treated with a combination of ESWT and the dietary supplement (DS) Tendisulfur Forte. Tendisulfur Forte is a commercially available Dietary Supplement (DS) containing methylsulfonylmethane (MSM), hydrolyzed swine collagen (Type I and Type II), [l]{.smallcaps}-arginine and [l]{.smallcaps}-lysine, vitamin C, Condroitin Sulfate, Glucosamine, *Curcuma longa* extracted to obtain curcuminoids, dry *Boswellia serrata* extracted to obtain acetyl-11-keto-*β*-boswellic acid (AKBA), and Myrrh. The dietary supplement was consumed twice a day for 1 month, then once a day for an additional month. We advised patients to take the dietary supplement at roughly the same time every day on an empty stomach in order to increase its bioavailability. VAS was selected to measure the perceived pain intensity, by asking the patient to report a value between 0--10 cm along a horizontal line (10 = severe pain; 0 = no pain). A two-centimeter change was considered clinically relevant[@CIT0006].

In addition, clinical functional evaluation was performed using different scores.

For patients with Achilles tendinopathy, VISA-A score was chosen. VISA-A is a questionnaire that contains eight questions, and gives information about: pain, functional status, and activity (= three significant domains of dysfunction). The final score has a range from 0--100 points[@CIT0006] ([Table 1](#t0001){ref-type="table"}).

###### 

Achilles tendinopathy group patient characteristics.

                           Control group   Tendisulfur group
  ------------------------ --------------- -------------------
  Number of patients       15              15
  Mean age (range)         51 (39--67)     46 (39--56)
  Male                     7               10
  Female                   8               5
  Symptoms onset (range)   6 (2--12)       5 (3--6)
  Right side               8 (53%)         9 (60%)
  Left side                5 (33%)         6 (40%)
  VISA-A                   7 (6--8)        7 (6--8)
  NSAIDs                   8 (53%)         9 (60%)

Table showing mean age in years, male and female sub-division, time from symptom onset in months, affected side, VISA-A assessment score at t0, and proportion of patients taking NSAIDs at t0.

Patients with shoulder tendinopathy were evaluated with the UCLA (University of California Los Angeles) shoulder score, a 4-item combined patient--clinician survey that reports pain, function, range of motion (ROM), and strength. Each item has a score ranging from 0--10 (a perfect score = 30) ([Table 2](#t0002){ref-type="table"}).

###### 

Shoulder tendinopathy group patient characteristics.

                           Control group   Tendisulfur group
  ------------------------ --------------- -------------------
  Number of patients       15              15
  Mean age (range)         52 (42--69)     55 (41--59)
  Male                     6               4
  Female                   9               11
  Symptoms onset (range)   12 (5--18)      6 (3--12)
  Right side               7 (47%)         9 (60%)
  Left side                4 (27%)         5 (33%)
  UCLA score               15 (11--20)     18 (15--20)
  NSAIDs                   9 (60%)         12 (80%)

Table showing mean age in years, male and female sub-division, time from symptom onset in months, affected side, UCLA assessment score at t0, and proportion of patients taking NSAIDs at t0.

Patients with lateral elbow tendinopathy were assessed with Mayo Elbow Performance Score (MEPS). This score is a widely used performance index for evaluation of clinical outcomes for a variety of elbow disorders. It consists of an evaluation of pain, arc of motion, stability, and patient rating of daily function, ranging from 0--100 points. A higher score indicates a better prognosis[@CIT0012] ([Table 3](#t0003){ref-type="table"}).

###### 

Elbow (epicondylitis) tendinopathy group patient characteristics.

                           Control group   Tendisulfur group
  ------------------------ --------------- -------------------
  Number of patients       15              15
  Mean age (range)         45 (36--57)     44 (31--54)
  Male                     6               7
  Female                   9               8
  Symptoms onset (range)   5 (3--8)        5 (3--7)
  Right side               8 (53%)         10 (67%)
  Left side                7 (47%)         5 (33%)
  Mayo scale               65 (55--70)     70 (65--80)
  NSAIDs                   8 (53%)         10 (67%)

Table showing mean age in years, male and female sub-division, time from symptom onset in months, affected side, Mayo Scale assessment score at t0, and proportion of patients taking NSAIDs at t0.

All 90 patients were subjected to one cycle of three high-energy Extracorporeal Shock Wave Therapy sessions, performed once a week for three consecutive weeks, with 1,700--2,000 shocks applied with a flux energy density of 0.12--0.35- mJ/mm^2^ using a Storz Medical Duolith SD1a machine. Patients affected by Achilles tendinitis were treated in a prone decubitus with the foot off the edge of the visitation table, allowing the ankle to be in its neutral position ([Figure 1](#F0001){ref-type="fig"}). Otherwise, patients affected by shoulder tendinopathy were subjected to ESWT in a sitting position with the superior limb positioned at 90° of elbow flexion, as well as patients affected by lateral epicondylitis. In the first case, a supine position of the palm was requested, aiming for a better exposure of the long head of the biceps ([Figure 2](#F0002){ref-type="fig"}). Instead, in the second case the palm was positioned in prone position ([Figure 3](#F0003){ref-type="fig"}). The trigger points were identified by palpation of the painful areas during the first physical examination and later were balanced through shock waves. Energy density was set up at 0.12 mJ/mm^2^ for all the patients and progressively raised up to 0.35 mJ/mm^2^ if the pain was bearable. For patients who didn't bear the pain the energy density was individually adapted observing the aforementioned range, in order to perform ESWT without any interruption.

![ESWT performed to the Achilles tendon.](IJDA_A_1605370_F0001_C){#F0001}

![ESWT performed to the shoulder.](IJDA_A_1605370_F0002_C){#F0002}

![ESWT performed to the elbow.](IJDA_A_1605370_F0003_C){#F0003}

All the patients were evaluated using VAS and the specific functional scores at the following stages: pre-treatment (t0), at 7 days (t1), at 30 days (t2), and after 60 days (t3).

This study was conducted following the principles of the Declaration of Helsinki and with the patients' permission expressed through written consent.

Inclusion/exclusion criteria {#s0003}
============================

We recruited patients between 18--70 years of age (mean age = 49 years**)** presenting with complaints for at least 1 month and with clinical (functional tests and VAS) and imaging studies (Xray, Ultrasound, MRI) confirming tendinopathy.

Exclusion criteria included: prior tendon rupture or surgery, systemic inflammatory diseases, diabetes, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), Gastroesophageal Reflux Disease (GERD), and intolerance or allergies to any single ingredient of Tendisulfur Forte. Moreover, we excluded all the patients who showed contraindications to ESWT (Pacemaker, pregnancy, systemic or in-situ neoplasia, local infection, history of epilepsy, severe coagulopathies)[@CIT0006].

Statistical analysis {#s0004}
--------------------

For each studied pathology, the mean average of both and respective functional scores was calculated at each time interval during the course of the study (t0 = pre-treatment, t1 = 7 days, t2 = 30 days, t3 = 60 days). Values were compared between each group for each pathology at corresponding follow-ups. *p*-values were calculated at each time interval. The Student *T*-test and *Z*-score were used to calculate differences between values. Intra-group trajectories and inter-group difference at each time interval were calculated using the Bonferroni correction. Statistical significance was set at *p* \< 0.05.

Results {#s0005}
=======

All study groups, sub-divided by pathology, were similar and uniform in terms of distribution of age, sex, and affected side.

In the treatment of shoulder tendinopathy, the Tendisulfur Forte group had significant results compared to the control group for both UCLA (*p*-value = 0.0002) and VAS scores (*p*-value \< 0.0001) at 60 days follow-up ([Figures 4](#F0004){ref-type="fig"} and [5](#F0005){ref-type="fig"}). NSAIDs consumption was significantly decreased in the Tendisulfur Forte group at 30 (*p*-value = 0.0308) and 60 days (*p*-value = 0.0061) ([Table 4](#t0004){ref-type="table"}).

![Within-group trajectories and between-group within-time difference for shoulder VAS scores.](IJDA_A_1605370_F0004_C){#F0004}

![Within-group trajectories and between-group within-time difference for shoulder UCLA scores.](IJDA_A_1605370_F0005_C){#F0005}

###### 

Shoulder tendinopathy results.

                      t0 (pre-treatment)   t1 (7 days)   t2 (30 days)   t3 (60 days)
  ------------------- -------------------- ------------- -------------- --------------
  Control group       15                   15            15             15
  UCLA (range)        15 (11--20)          19 (14--22)   20 (16--24)    23 (17--25)
  VAS (range)         7 (6--8)             6 (4--7)      5 (4--6)       5 (4--7)
  NSAIDs (%)          9 (60%)              9 (60%)       6 (40%)        6 (40%)
  Tendisulfur group   15                   15            15             15
  UCLA (range)        18 (15--20)          18 (16--22)   23 (20--25)    27 (26--29)
  VAS (range)         7 (6--8)             7 (6--7)      5 (4--6)       2 (1--3)
  NSAIDs (%)          12 (80%)             5 (33%)       1 (7%)         0 (0%)
  p-value UCLA        0.3117               0.3240        0.1510         0.0002
  p-value VAS         0.8480               0.7811        0.2467         \<0.0001
  p-value NSAIDs      0.2301               0.1443        0.0308         0.0061

Table showing shoulder outcomes at 7, 30, and 60 days after treatment. VAS and UCLA values are shown as means with ranges. NSAIDs percentages are to be intended as patients who reported taking NSAIDs at specific intervals. *p*-values are given for UCLA, VAS scores, and NSAIDs consumption between groups pre-treatment and at each follow-up.

When treating epicondylitis with ESWT + Tendisulfur Forte, we saw an early significant improvement in pain reduction at the 7th day follow-up (*p*-value = 0.0024), with subsequent follow-up showing increased improvement (*p*-value \< 0.00001) ([Figure 6](#F0006){ref-type="fig"}). Mayo scores showed significant results in the Tendisulfur Forte group as compared to the Control group at 30 days and 60 days from the start of the treatment (*p*-value = 0.0004 and *p*-value \< 0.00001, respectively) ([Figure 7](#F0007){ref-type="fig"}). Patients in the study group consumed significantly less NSAIDs than in the control group at the 30 and 60 day follow-ups (*p*-value = 0.0001 and *p*-value = 0.0053, respectively) ([Table 5](#t0005){ref-type="table"}).

![Within-group trajectories and between-group within-time difference for elbow VAS scores.](IJDA_A_1605370_F0006_C){#F0006}

![Within-group trajectories and between-group within-time difference for Mayo elbow scores.](IJDA_A_1605370_F0007_C){#F0007}

###### 

Elbow tendinopathy (epicondylitis) results.

                      t0 (pre-treatment)   t1 (7 days)   t2 (30 days)   t3 (60 days)
  ------------------- -------------------- ------------- -------------- --------------
  Control group       15                   15            15             15
  Mayo (range)        65 (55--70)          70 (55--70)   70 (60--75)    70 (65--80)
  VAS (range)         7 (7--8)             8 (7--8)      6 (5--7)       6 (5--6)
  NSAIDs (%)          8 (53%)              8 (53%)       8 (53%)        8 (53%)
  Tendisulfur group   15                   15            15             15
  Mayo (range)        18 (15--20)          18 (16--22)   23 (20--25)    27 (26--29)
  VAS (range)         7 (6--8)             7 (6--7)      5 (4--6)       2 (1--3)
  NSAIDs (%)          10 (67%)             3 (20%)       0 (0%)         1 (7%)
  *p*-value Mayo      0.3429               0.2275        0.0004         \<0.00001
  *p*-value VAS       0.443                0.0024        \<0.00001      \<0.00001
  *p*-value NSAIDs    0.4533               0.0588        0.0001         0.0053

Table showing shoulder outcomes at 7, 30, and 60 days after treatment. VAS and UCLA values are shown as means with ranges. NSAIDs percentages are to be intended as patients who reported taking NSAIDs at specific intervals. *p*-values are given for Mayo, VAS scores, and NSAIDs consumption between groups pre-treatment and at each follow-up.

VISA-A scores in Achilles tendinopathy were significant in the Tendisulfur group at each follow-up, with the greatest significance observed at t2 (*p*-value \< 0.00001) ([Table 5](#t0005){ref-type="table"}). Mean VISA-A scores had a greater improvement in the Tendisulfur Forte group, +27 (+39%) as compared to the control group, +7 (17%) ([Figure 8](#F0008){ref-type="fig"}). VAS saw a significant reduction at day 7 in patients consuming Tendisulfur Forte (*p*-value = 0.0179) with subsequent follow-up showing a further decrease in VAS values ([Figure 9](#F0009){ref-type="fig"}). Reduction of NSAID consumption was significant at 30 days (*p*-value = 0.0143) and at 60 days (*p*-value = 0.0143) ([Table 6](#t0006){ref-type="table"}).

![Within-group trajectories and between-group within-time difference for Achilles tendinopathy VAS scores.](IJDA_A_1605370_F0008_C){#F0008}

![Within-group trajectories and between-group within-time difference for Achilles VISA-A scores.](IJDA_A_1605370_F0009_C){#F0009}

###### 

Achilles tendinopathy results.

                      t0 (pre-treatment)   t1 (7 days)   t2 (30 days)   t3 (60 days)
  ------------------- -------------------- ------------- -------------- --------------
  Control group       15                   15            15             15
  VISA-A (range)      42 (36--60)          42 (38--60)   47 (43--65)    49 (45--65)
  VAS (range)         7 (6--8)             7 (6--7)      5 (4--6)       5 (4--6)
  NSAIDs (%)          8 (53%)              5 (33%)       5 (33%)        3 (20%)
  Tendisulfur group   15                   15            15             15
  VISA-A (range)      70 (53--85)          78 (64--88)   88 (77--96)    97 (85--100)
  VAS (range)         7 (6--8)             6 (5--7)      4 (3--4)       2 (0--3)
  NSAIDs (%)          9 (60%)              4 (27%)       0 (0%)         0 (0%)
  *p*-value VISA-A    0.0013               \<0.00001     \<0.00001      \<0.00001
  *p*-value VAS       0.5322               0.0179        0.0014         \<0.00001
  *p*-value NSAIDs    0.7114               0.6892        0.0143         0.0143

Table showing shoulder outcomes at 7, 30, and 60 days after treatment. VAS and UCLA values are shown as means with ranges. NSAIDs percentages are to be intended as patients who reported taking NSAIDs at specific intervals. *p*-values are given for VISA-A, VAS scores, and NSAIDs consumption between groups pre-treatment and at each follow-up.

We note that nearly all patients (44/45) in the Tendisulfur Forte groups were NSAID-free at 60 days follow-up. In addition, we observed that, during the course of the study, and the subsequent follow-up period (up to 2 months) there was a significant reduction of NSAIDs consumption in the Tendisulfur Forte group ([Figure 10](#F0010){ref-type="fig"}).

![Graph Showing overall NSAIDs consumption, taking into consideration all participants from the Tendisulfur Forte group and the control groups.](IJDA_A_1605370_F0010_C){#F0010}

We report no adverse effects from the dietary supplement with no discontinuation and good overall tolerability during ESWT session in both groups.

Discussion {#s0006}
==========

Tendinopathies affect a relevant part of the population. In particular, they affect young and active people due to stress and overuse, as well as the elderly because of tendon degeneration. Among the most frequent tendinopathies, we can distinguish: Rotator cuff tendinopathy, lateral epicondylitis, and insertional Achilles tendinopathy[@CIT0013]. According to different studies, lower limb tendinopathies are more related to overuse, as in the case of sports and physical recreational activities, while rotator cuff tendinopathy is most likely linked to degeneration[@CIT0014].

The risk of recurrence is very high, and a definite therapy is still not available[@CIT0006].

Standard treatment regimens of these diseases include rest, cryotherapy, activity modification, stretching exercises, NSAIDs, and eccentric loading.

Several physical therapies include extracorporeal shock waves, Tecar therapy, cryo-us, and physiotherapy[@CIT0015].

In regards to Tecar therapy, it is a type of "thermotherapy", specifically based on deep heat production in body tissues. It is indicated to treat joint and muscular pathologies, traumas, tendinopathies, neuropathies, and acute or chronic pain[@CIT0016] ^,^ [@CIT0017].

Evidence on the efficacy of the use of exercise as a conservative therapy to treat pain and functional disability are reported in the literature[@CIT0018] ^,^ [@CIT0019].

ESWT, initially introduced for the treatment of nephrolithiasis, has become a viable option for the treatment of different soft-tissue disorders[@CIT0008] such as calcific tendinopathy of the rotator cuff, lateral elbow tendinopathy, and insertional Achilles tendinopathy. ESWT modifies cell membrane and cytoplasm organelles, resulting in nucleus stimulation. All of these changes lead to synthesis of proteins, nitric oxide (NO), and specific growth factors (GF) which activate several biological processes[@CIT0007]. Erroi *et al*.[@CIT0020] demonstrated that both ESWT and platelet-rich plasma (PRP) injections are effective in the treatment of insertional Achilles tendinopathy in people who participate in sports. PRP is a concentrate of platelet-rich plasma protein derived from the patient's own blood containing growth factors, with healing, regeneration, and anti-inflammatory effects[@CIT0021]. Lee *et al*.[@CIT0024] have reported optimal outcomes after ESWT in the treatment of chronic refractory Achilles tendinopathy.

Frassanito *et al*.[@CIT0025] stated that a treatment of kinesio taping, followed by ESWT, can be an effective treatment in patients affected by calcific shoulder tendinopathy. Kinesio taping indeed can be considered an adjuvant therapy, which improves the regenerative effects of ESWT.

Li *et al*.[@CIT0026] have demonstrated the effectiveness of ESWT in shoulder pain relief in patients affected by chronic rotator cuff tendinopathy.

Moreover, Vulpiani *et al*.[@CIT0027] showed that ESWT had better clinical outcomes at 6 and 12 months follow-up when compared to Cryo-US in the treatment of symptomatic chronic lateral epicondylitis.

A more recent retrospective study, conducted by Chou *et al*.[@CIT0028], underlined the effectiveness of performing ESWT in the management of chronic rotator cuff tendinitis or partial tears of the rotator cuff before undergoing surgery. They compared two groups of patients, an athletic group and a non-athletic group, and observed a faster recovery with a rate of satisfaction greater than 50% in both groups.

In recent years, there has been an introduction of dietary supplements tailored for degenerative and/or inflammatory joint pathologies. Nutraceuticals are not pharmacologic in their nature, and contain compounds that have been scientifically proven to have modulatory effects on inflammation. In light of these considerations, nutraceutical supplements are widely adopted in the general and athletic population, aimed at the reduction of symptoms, and prevention of tendon injuries[@CIT0001]. One of these products is Tendisulfur Forte. It contains methylsulfonylmethane (MSM), hydrolyzed swine collagen (Type I and Type II), [l]{.smallcaps}-arginine and [l]{.smallcaps}-lysine, vitamin C, Condroitin Sulfate, Glucosamine, *Curcuma longa* extracted to obtain curcuminoids, dry *Boswellia serrata* extracted to obtain acetyl-11-keto-*β*-boswellic acid (AKBA), and Myrrh.

It is widely accepted in the clinical practice that nutritional components could play a significant role in tendon healing, as shown by several other studies[@CIT0001].

Methylsulfonylmethane (MSM) is a sulfur-containing compound. It is a natural component of vegetables, grains, fruits, and beverages. Through oral administration it is rapidly absorbed, well distributed, and completely excreted from the body. Fusini *et al*.[@CIT0001] state that it can be an efficacious analgesic and anti-inflammatory supplement. Its employment in the management of osteoarthritis showed a rapid reduction of pain and swelling while improving functional ability. In the literature, it is reported that MSM may have clinical applications for arthritis and other inflammatory disorders such as interstitial cystitis, allergic rhinitis, and acute exercise-induced inflammation. The mechanism of action includes the prevention of degradation of the NF-kB inhibitor, blocking of phosphorylation of the p65 subunit at Serine-536, the downregulation of the expression of inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) through suppression of NF-kB[@CIT0029].

Vitamin C is a co-enzyme of proline hydroxylase, involved in the synthesis of procollagen chains[@CIT0001] ^,^ [@CIT0030]. For this reason, an appropriate concentration of vitamin C is indispensable for normal development of tendons. Nevertheless, vitamin C is not able to increase collagen secretion; however, it is an anti-oxidative agent, that enhances the mechanical and thermal stability of rat tail tendons, as stated in a review of Fusini *et al*.[@CIT0001].

Another experimental study, performed by Omeroglu *et al*.[@CIT0031], demonstrated that parenteral supplementation of high-dose vitamin C (once daily, every 2 days) accelerates the Achilles tendon healing in a healthy rat model. The mechanism of action seems to depend on improvement of angiogenesis in the early stage, and of type I collagen synthesis during healing[@CIT0031]. Nevertheless, in a more recent paper, Gemalmaz *et al*.[@CIT0032] investigated the effects of a dietary supplement containing mucopolysaccharides, vitamin C, and collagen on Achilles tendon's healing in rats, showing no advantages in collagen synthesis after 3 weeks. However, it must be noted that the rats which received the supplement showed an increase in TGF-*ß* and proliferating cell nuclear antigen (PCNA) in the endotenon fibroblasts of the healing site, suggesting a possible role of tendon healing.

Boswellia species have been demonstrated to have anti-inflammatory effects through the inhibition of cytokine production in human monocytes in vitro, as well as cytotoxic activity. This is likely due to inhibition of nuclear factor kappa B (NF-kB) signaling by neutrophilic granulocytes, resulting in downregulation of pro-inflammatory cytokines (such as TNF-*α*, IL-1, IL-2, IL-4, IL-6, and IFN-*γ*) as well as reduction of NF-kB-dependent anti-apoptotic gene expression[@CIT0001] ^,^ [@CIT0033]. Other possible mechanisms are the inhibition of 5-lipoxygenase and leukotriene biosynthesis in neutrophilic granulocytes, along with the depression of the elastase enzyme activity.

Additionally, Boswellia prevents the TNF *α*-induced expression of matrix metalloproteinases MMP-3, MMP-10, and MMP-1237. It can suppress the conversion of C3 into C3a and C3b in the classic pathway of the complement system[@CIT0001].

Curcumin is a natural polyphenol with antioxidant properties derived from Curcuma Longa[@CIT0001]. Its mechanisms of action are based on modulation of transcription factors such as NFkB, AP-1, b-catenin peroxisome proliferator-activated receptor-c, enzymes (COX-2 and 5-LOX), inducible NOS, pro-inflammatory cytokines (TNF-a, IL-1b, and IL-6), and cell surface adhesion molecules[@CIT0033].

L-arginine and l-lysine are essential amino acids involved in the synthesis of elastase.

Moreover, l-arginine is involved in the production of NO by the constitutive enzyme endothelial NO oxide synthase (eNOS). NO leads to the vasodilation of blood vessels resulting in increased blood flow[@CIT0034]. During the healing process, the formation of NO is an indispensable step because its inhibition increases the level of TGF-*β*, therefore leading to fibrosis and chronic inflammation[@CIT0001].

There is much evidence of a possible role of NO in the management of pain and range of motion in tendinopathies[@CIT0035].

Myrrh is a natural anti-inflammatory compound. Morikawa *et al*.[@CIT0038] showed that myrrh contains several anti-inflammatory constituents, called terpenoids, which are able to inhibit nitric oxide production in lipopolysaccharide (LPS)-activated mouse peritoneal macrophages.

Gumina *et al*.[@CIT0034] demonstrated that an oral supplement containing methylsulfonylmethane, arginine L-alpha-ketoglutarate, hydrolyzed type I collagen bromelain, and grape juice (Tenosan), could reduce shoulder pain and improve healing of large rotator cuff tears after arthroscopic repair.

Merolla *et al*.[@CIT0033] used a dietary supplement containing Boswellia serrata and Curcumalonga (Tendisulfur, LaborestSpA, Nerviano, Italy), which showed short-term effectiveness in post-operatively reducing pain after rotator cuff tear repair surgery.

Notarnicola *et al*.[@CIT0006] evaluated the efficacy of combined treatment with ESWT and arginine supplementation in patients with Achilles tendinopathy, observing an improvement of the therapeutic response.

Another interesting study was conducted by Balius *et al*.[@CIT0039], who evaluated the effects of an oral supplement composed by mucopolysaccharides, type I collagen, and vitamin C in the treatment of Achilles tendinopathy. Their results show that the combination of the aforementioned supplement and either eccentric training or passive stretching provides further benefits compared to physical therapy alone.

Considering the wide consensus of ESWT in the literature, we believe that ESWT represents the best physical therapy to provide an effective recovery for tendinopathies, and Tendisulfur Forte may be useful in reducing inflammation and the possibility of recurrence because of its key features. Indeed, shock wave therapy increases bioavailability of the supplement to the tendon tissue[@CIT0006], due to the neo-angiogenic properties of ESWT[@CIT0040] ^,^ [@CIT0041]. To confirm the positive effect of the association of Tendisulfur Forte and ESWT, our study showed that patients in the Tendisulfur Forte group reduced their use of NSAIDs during the 2 months of treatment when compared to the control group. Moreover, we observed a greater decrease of pain in the Tendisulfur Forte group and an improvement of tendon healing after 30 days of treatment.

We report no side-ffects in all patients treated with Tendisulfur Forte.

Limits {#s0007}
------

The limits of our study include the small number of patients for each group and lack of randomization in group allocation. The reason for the lack of randomization was in order to take into consideration regimen compliance and allergies patients might have to any of the components of Tendisulfur Forte. Moreover, we do not have functional scores for the patients after 2 months follow-up, as well as an instrumental monitoring with US or MRI after the therapy.

Conclusions {#s0008}
===========

Our results show that the combination of ESWT and Tendisulfur Forte provides a greater and faster pain relief, with a significant reduction of NSAIDs consumption and without side-effects. Therefore, we believe that the combination of the aforementioned treatments could be considered as a valid first-line treatment for the most frequent tendinopathies. As a future prospective it could be interesting to evaluate the effects of a two-stage treatment based on ESWT and nutraceutical supplementation performed separately. Indeed, this different approach could clarify the role of both the therapies on the reduction of inflammation and the improvement of functionality in order to optimize their combination.
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